his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
This strategic decision will unlock significant value for our scientific and industrial products business
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
Subscribe To Our Newsletter & Stay Updated
